Similarly, mutations in GNAS, KRAS, or both genes did not appear to be associated with any of the clinicopathological features of IPMN (sex, age, morphologic variation, et. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.